Portola Pharmaceuticals Inc (PTLA): Portola Pharmaceuticals' CEO Presents at ... Seeking Alpha Targeting not only B cell signaling but cytokine signaling via JAK we think is potential beneficial for patients that are not addressed by the other agents including Ibrutinib PI3 kinase inhibitors, rituximab. We have an ongoing, as I said, Phase I/II ... |
